Date: 2012-11-26
Type of information:
phase:
Announcement:
Company: Galapagos (Belgium)
Product: new undisclosed class of antibiotics
Action mechanism: This newly discovered antibiotic works by inhibiting the target DNA pol III alpha, an enzyme present in all bacteria and essential for their growth; this target is absent in humans. The novel mode of action - inhibition of DNA pol III alpha - may be used to explore a variety of novel antibiotics, targeting bacteria for which resistance to current antibiotics has emerged.
Disease: multiple drug-resistant (MDR) infections
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest news: Galapagos has announced that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains. Using this novel target, Galapagos has selected a first candidate antibiotic, CAM-1, to enter drug development. CAM-1 was tested against more than 250 different bacterial strains and effectively killed 100% of all drug resistant Staph. aureus, including MRSA. CAM-1 shows better efficacy than standard antibiotics, as shown by in vivo bacterial infection models. Galapagos aims to enter the clinic in the first quarter 2014, with a Proof of Concept study thereafter. This novel antibiotic program, including all compounds targeting MRSA, is fully proprietary to Galapagos.
